Earnings Call Summary | CLINUVEL PHARMACEUTICALS LTD SPON ADR EA REP 1 ORD NPV(CLVLY.US) Q2 2023 Earnings Conference
Earnings Call Summary | CLINUVEL PHARMACEUTICALS LTD SPON ADR EA REP 1 ORD NPV(CLVLY.US) Q2 2023 Earnings Conference
The following is a summary of the Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2023 Earnings Call Transcript:
以下是Clinuvel Pharmicals Limited（CLVLY）2023年第二季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Clinuvel Pharmaceuticals reported a 15% increase in total revenue and other income in Q2 2023 compared to the same period in 2022. Commercial sales and sales reimbursement revenue grew by 9.9%.
Expenses rose by 28% to reflect the expanded activities of the group.
Profit before tax rose 1% to 14.8 million, but profit after tax declined by 4% to 10.9 million leading to an EPS of 22.1 cents due to increased tax expense.
The balance sheet at the end of June 2023 showed an 8.5% increase in net asset position to 178.6 million, and 211.7 million in total assets.
Cash and term deposits grew 11% to 174.5 million Australian dollars.
Clinuvel Pharmicals報告稱，與2022年同期相比，2023年第二季度的總收入和其他收入增長了15％。商業銷售和銷售報銷收入增長了9.9％。
支出增長了28％，這反映了該集團活動的擴大。
由於稅收支出的增加，稅前利潤增長了1％，至1,480萬英鎊，但稅後利潤下降了4％，至1,090萬英鎊，每股收益爲22.1美分。
2023年6月底的資產負債表顯示，淨資產狀況增長了8.5％，達到1.786億英鎊，總資產增長了2.117億美元。
現金和定期存款增長了11％，達到1.745億澳元。
Business Progress:
業務進展：
Growth in revenue use through treatments in both Europe and the USA has been underpinned by an increase in the number of treatment centers and the patient retention rate.
Clinuvel invested in UK property assets to accommodate its growing European workforce.
Clinuvel aims to expand via rigorous R&D efforts after 2025, with planned CapEx in future office facilities in other business-sensible areas.
Significant strides are being made in various areas, including vitiligo, DNA repair, stroke, and porphyria.
Anticipated clinical results and several updates expected from Clinuvel's various projects throughout the year, demonstrating their future growth and expansion plans.
歐洲和美國治療收入的增長是由治療中心數量和患者留存率的增加所支撐的。
Clinuvel投資了英國房地產資產，以適應其不斷增長的歐洲勞動力。
Clinuvel的目標是在2025年之後通過嚴格的研發工作進行擴張，計劃將資本支出用於其他商業敏感領域的未來辦公設施。
包括白癜風、DNA修復、中風和卟啉症在內的各個領域都取得了重大進展。
預期的臨床結果和全年Clinuvel各個項目的幾項更新預計將顯示其未來的增長和擴張計劃。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。